EGM
DSGN icon

Engineers Gate Manager’s Design Therapeutics DSGN Stock Holding History

Engineers Gate Manager’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$171K Buy
16,090
+2,078
+15% +$21K ﹤0.01% 1948
2025
Q4 		$131K Buy
+14,012
New +$110K ﹤0.01% 1877
2024
Q1 		– Sell
-17,914
Closed -$47.5K – 2002
2023
Q4 		$47.5K Buy
+17,914
New +$41K ﹤0.01% 1848

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Engineers Gate Manager's DSGN Position: Q1 2026 in Review

Engineers Gate Manager increased its Design Therapeutics (DSGN) stake by 15% in Q1 2026, buying an estimated $21K and bringing the position to 16,090 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #1948.

Engineers Gate Manager first reported a position in DSGN in Q4 2023 and has held it in 3 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Engineers Gate Manager held 16,090 shares of Design Therapeutics worth $171K as of Q1 2026.
  • Engineers Gate Manager bought 2,078 Design Therapeutics shares in Q1 2026, an estimated $21K.
  • Design Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q1 2026, its #1948 holding.
  • Engineers Gate Manager first reported a position in Design Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.